⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Table S3 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma

Alyssa C. Flint Dana K. Mitchell Steven P. Angus Abbi E. Smith Waylan Bessler Li Jiang Henry Mang Xiaohong Li Qingbo Lu Brooke Rodriguez George E. Sandusky Andi R. Masters Chi Zhang Pengtao Dang Jenna Koenig Gary L. Johnson Weihua Shen Jiangang Liu Amit Aggarwal Gregory P. Donoho Melinda D. Willard Shripad V. Bhagwat D. Wade Clapp Steven D. Rhodes

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Pharmacokinetic properties of LY3214996 and abemaciclib

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Flint et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523906 https://doi.org/10.1158/1078-0432.27032773.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S3 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma2024
2Table S3 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma2024
3Table S3 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma2024
4Figure S8 from Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma2024
5Figure S8 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma2024